Watch the Novel Cohorts podcast with special guest Omer Saka from Roland Berger
In this episode of the Novel Cohorts podcast, Dan Housman (Graticule) and Omer Saka (Roland Berger) dive into how digital technologies are reshaping drug development through the concept of the Digitally Enabled Target Product Profile (DeTPP). They explore how strategic digital integration rather than ad-hoc tool adoption can enhance value delivery, improve patient outcomes, close evidence gaps, and strengthen payer engagement.
Some key takeaways from the discussion are:
- Real value is unlocked when digital tools are embedded early to address evidence gaps, enable follow-up, and support real-world effectiveness
- Traditional TPPs often miss real-world patient behavior—future TPPs must integrate patient-reported outcomes and engagement.
- Data capture & analytics, personalization tools , and information exchange platforms for patients and providers form the three pillars of digital enablement
- To avoid fragmented tech adoption, companies must design digitally enabled TPPs as part of a structured, cost-effective, and scalable evidence plan
Watch the video to learn more about how DeTTP is shaping the future of drug development.